Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

MaxCyte, Inc.

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA™ therapies for its own pipeline. CARMA is MaxCyte’s mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, MaxCyte leverages its Flow Electroporation® Technology platform to enable its biopharma partners to advance the development of innovative, cutting-edge medicines, particularly in cell therapy, including the use of gene editing tools in the treatment of inherited genetic diseases and immuno-oncology approaches. The Company has placed its cutting-edge instruments worldwide, including with 9 of the top 10 global biopharma companies, and has 55+ partnered program licenses in cell therapy including 25+ licensed for clinical use. MaxCyte helps its partners to unlock the full potential of their products.

  • Date:Tuesday, February 12
  • Time:10:45 AM - 11:00 AM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23403
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Introduce Company
  • Company Website:www.maxcyte.com
  • Company HQ City:Gaithersburg
  • Company HQ State:Maryland
  • Company HQ Country:United States
  • Market Cap:Approx $150M USD
  • Ticker:MXCT
  • Exchange:LSE AIM
  • CEO/Top Company Official:Douglas A. Doerfler
  • Year Founded:1998
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:MCY-M11
  • Development Phase of Primary Product:Phase I
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):2
Speakers
Douglas Doerfler
MaxCyte, Inc.
Back